An innovative B2B software startup changing how biotech and pharma companies evaluate drug target safety for effective decision-making
Sable Bio has raised €4.9M across 2 funding rounds from 4 investors, most recently a Seed round in Feb 2026. Based in London, UK; active in Software. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-02-11 | Seed | €3.2M | Episode 1 Ventures,MMC Ventures,Seedcamp | View deal → |
| 2024-02-06 | Pre-Seed | €1.7M | Episode1 Ventures,Seedcamp | View deal → |
